Claim Missing Document
Check
Articles

Found 3 Documents
Search

The Wound Healing Potential of Honey and Propolis from Stingless Bees in Acute Wounds Wafi, Viky Hibatu; Arius, Yudhy; Tua, Ivan Joalsen Mangara; Paramita, Swandari; Sawitri, Endang
MAHESA : Malahayati Health Student Journal Vol 5, No 7 (2025): Volume 5 Nomor 7 (2025)
Publisher : Universitas Malahayati

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33024/mahesa.v5i7.18933

Abstract

ABSTRACT Honey and propolis from stingless bees have been reported to promote wound healing due to their anti-inflammatory, antioxidant, antibacterial, and moisturizing activities. However, variations in compounds and biological activities of these products can arise due to geographical and bee origin differences. This study aimed to investigate the wound healing potential of stingless bee honey and propolis from East Kalimantan in an acute wound animal model. Honey and propolis from stingless bees have been reported to promote wound healing due to its anti-inflammatory, antioxidant, antibacterial, and moisturizing activities. However, variation of compounds and biological activities of these products can arise due to geographical and bee origin differences. This study aimed to investigate the wound healing potential of stingless bee honey and propolis from East Kalimantan in acute wound animal model. A post-test only control group design was employed in this study. Fifteen Wistar rats were divided into 3 groups, i.e., a control receiving tulle and treatment groups receiving stingless bee honey and propolis, respectively. Wound healing activity was evaluated from wound diameter changes and histological evaluations following hole punch wound. Kruskal Wallis test results showed no significant changes in the proliferation phase of wound healing, as reflected by the diameter changes (p = 0.989), the rate of histopathological re-epithelization (p = 0.730) as well as number of fibroblasts (p = 0.779), collagen (p = 0.779), and neovascularization (p = 0.756) among the groups. Honey and propolis from stingless bees have the potential to treat acute wounds in the proliferation phase where their wound healing properties are equivalent to tulle. Keywords: Acute Wound, Stingless Bee, Honey, Propolis.
Surgical Management of Vascular Anomalies in Extremities: A Case Series Permatasari, Gita; Tua, Ivan Joalsen Mangara
Journal of Indonesia Vascular Access Vol. 4 No. 1 (2024): (Available online : June 2024)
Publisher : Indonesian Vascular Access Association (IVAA)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/jinava.v4i1.47

Abstract

Introduction: Vascular malformations and vascular tumors are the two categories of vascular anomalies in the ISSVA categorization system. Although surgery has historically been the primary method of treating vascular abnormalities, it is increasingly frequently combined with other procedures. Thus, the purpose of this study is to outline the several surgical approaches for treating vascular abnormalities in the extremities. Case: In this series study revealed six patiens with vascular malformation who underwent surgical treatment. The locations of the lession more frequently in lower extremity than upper extremity. Few cases need reconstrution using flap or skin graft. Three cases were recurrent hemangiomas which underwent surgical excision before this study. In the follow-up, there were no signs of tumor reccurence after the secondary surgical excision. Four patients had combined therapy with scleroting agent.  Conclusion: Hence, surgical management is constantly the treatment of coice for vascular anomalies. Combined therapy with scleroting agent may use in the case which unable to do expansive excision.
Restenosis risk factor and the primary patency rate of arteriovenous fistula after initial percutaneous transluminal angioplasty: a retrospective cohort study Utari, Siti Ayu Meisa; Tua, Ivan Joalsen Mangara; Christian, David H; Caesario, Michael
Journal of Indonesia Vascular Access Vol. 5 No. 2 (2025): Available online : 1 December 2025
Publisher : Indonesian Vascular Access Association (IVAA)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/jinava.v5i2.67

Abstract

Background: Arteriovenous fistula (AVF) is the optimal vascular access for patients because of its prolonged patency and limited problems. Nevertheless, maintenance is sometimes obstructed by stenosis. This study aimed to determine the factors associated with restenosis and primary patency rate in 12 months after Percutaneous Transluminal Angioplasty  (PTA). Method: A retrospective study of patients who underwent initial PTA   between January 2018 and October 2023. The clinical variables, laboratory indicators, and surgical data were observed in this study. The restenosis factors were analyzed by univariate analysis, Cox - Regression test, and Hosmer-Lemeshow test. The Receiver Operating Characteristic (ROC) Analysis identified the cut-off Platelet Count (PC). The primary patency of AVF with restenosis risk was evaluated using the Kaplan-Meier analysis and log-rank test. Result: A total of 54 patients were included. The Cox proportional hazard model revealed PC (p=0.004) was a risk factor for AVF restenosis. The Hosmer-Lemeshow test (χ2 = 11.130, p = 0.194) indicates our logistic regression model fits the data. Analysis of ROC identified a cut-off value of PC ≥ 210.5 x 109/L (sensitivity 85.7 %, specificity 46.2%). Primary patency rates of AVF with PC ≥ 210.5 x 109/L at 6 and 12 months (64.1% and 35.8%) were lower than those with PC< 210.5 x 10 9 /L (80.0%, 66.6%). Conclusion: Balloon type (Drug Coated Balloon and Plain Balloon), predilating balloon, balloon diameter, and inflammatory markers showed no association with restenosis in 12 months after PTA. Platelet Count is statistically significant associated with AVF restenosis, which can predict the primary patency of  AVF after initial PTA. It assists physicians in establishing the follow-up schedule and appropriate intervention to prevent HD vascular access failure within 12 months post-PTA.